Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; altePlase was more frequently associated with symptomatic intracranial hemorrhage.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
- M. Patel, K. Mahaffey, R. Califf
- MedicineNew England Journal of Medicine
- 7 September 2011
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
- H. Heidbuchel, P. Verhamme, P. Kirchhof
- MedicineEuropace
- 1 October 2015
The current manuscript is an update of the original Practical Guide, published in June 2013, and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence.
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
In patients receiving intravenous t-PA for acute ischemic stroke, thrombectomy with the use of a stent retriever within 6 hours after onset improved functional outcomes at 90 days.
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
- W. Hacke, M. Kaste, M. Mahagne
- MedicineJAMA
- 4 October 1995
Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan, however, the identification of this subgroup is difficult.
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
- N. Wahlgren, N. Ahmed, G. Vanhooren
- MedicineThe Lancet
- 27 January 2007
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
- W. Hacke, G. Donnan, S. Hamilton
- Medicine, PsychologyThe Lancet
- 6 March 2004
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
- H. Heidbuchel, P. Verhamme, P. Kirchhof
- MedicineEuropace
- 1 May 2013
New oral anticoagulant drugs are an alternative for vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation (AF) and many unresolved questions on how to optimally use these drugs in specific clinical situations remain.
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
- Deepak L. Bhatt, K. Fox, E. Topol
- Medicine, BiologyNew England Journal of Medicine
- 20 April 2006
Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes.
...
...